The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Fructose-1,6-bisphosphatase opposes renal carcinoma progression
Open accessAbstract
Clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, is characterized by elevated glycogen levels and fat deposition. These consistent metabolic alterations are associated with normoxic stabilization of hypoxia-inducible factors (HIFs) secondary to von Hippel-Lindau (VHL) mutations that occur in over 90% of ccRCC tumours. However, kidney-specific VHL deletion in mice fails to elicit ccRCC-specific metabolic phenotypes and tumour formation, suggesting that additional mechanisms are essential. Recent large-scale sequencing analyses revealed the loss of several chromatin remodelling enzymes in a subset of ccRCC (these included polybromo-1, SET domain containing 2 and BRCA1-associated protein-1, among others), indicating that epigenetic perturbations are probably important contributors to the natural history of this disease. Here we used an integrative approach comprising pan-metabolomic profiling and metabolic gene set analysis and determined that the gluconeogenic enzyme fructose-1,6-bisphosphatase 1 (FBP1) is uniformly depleted in over six hundred ccRCC tumours examined. Notably, the human FBP1 locus resides on chromosome 9q22, the loss of which is associated with poor prognosis for ccRCC patients. Our data further indicate that FBP1 inhibits ccRCC progression through two distinct mechanisms. First, FBP1 antagonizes glycolytic flux in renal tubular epithelial cells, the presumptive ccRCC cell of origin, thereby inhibiting a potential Warburg effect. Second, in pVHL (the protein encoded by the VHL gene)-deficient ccRCC cells, FBP1 restrains cell proliferation, glycolysis and the pentose phosphate pathway in a catalytic-activity-independent manner, by inhibiting nuclear HIF function via direct interaction with the HIF inhibitory domain. This unique dual function of the FBP1 protein explains its ubiquitous loss in ccRCC, distinguishing FBP1 from previously identified tumour suppressors that are not consistently mutated in all tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hypoxia can provide energy to tumor cells by activating transcriptional programs that induce glucose uptake and glycolysis.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Hypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380
Self-citationReductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., et al. (2012) · Nature · doi:10.1038/nature10602 · Cited by 1,791
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693
Self-citationFunctional genomics reveal that the serine synthesis pathway is essential in breast cancer
Possemato, R., Marks, K. M., Shaul, Y. D., Pacold, M. E., Kim, D., Birsoy, K., Sethumadhavan, S., Woo, H.-K., Jang, H. G., Jha, A. K., et al. (2011) · Nature · doi:10.1038/nature10350 · Cited by 1,683
Rini, B. I., Campbell, S. C., & Escudier, B. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60229-4 · Cited by 1,634
Cohen, H. T., & McGovern, F. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043172 · Cited by 1,591
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
Varela, I., Tarpey, P. S., Raine, K. M., Huang, D., Ong, C. K., Stephens, P., Davies, H. R., Jones, D., Lin, M., Teague, J. W., et al. (2011) · Nature · doi:10.1038/nature09639 · Cited by 1,302
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 550
Bárcena‐Varela, M., Paish, H. L., Alvarez, L., Uriarte, I., Latasa, M. U., Santamaría, E., Recalde, M., Garate, M., Clavería-Cabello, A., Colyn, L., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-320205 · Cited by 96
Chowdhury, B., Porter, E. G. P., Stewart, J. C., Ferreira, C. R., Schipma, M. J., & Dykhuizen, E. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153718 · Cited by 102
Gelman, S. J., Naser, F. J., Mahieu, N. G., McKenzie, L. D., Dunn, G. P., Chheda, M. G., & Patti, G. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.050 · Cited by 95
Huang, L., Liu, D., Wang, N., Ling, S., Tang, Y., Wu, J., Hao, L., Luo, H., Hu, X., Sheng, L., et al. (2017) · Cell Research · doi:10.1038/cr.2017.146 · Cited by 96
Hypoxia Mediates Tumor Malignancy and Therapy Resistance
Luo, W., & Wang, Y. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12734-3_1 · Cited by 94
Fructose-1,6-Bisphosphatase 2 Inhibits Sarcoma Progression by Restraining Mitochondrial Biogenesis
Huangyang, P., Li, F., Lee, P., Nissim, I., Weljie, A. M., Mancuso, A., Li, B., Keith, B., Yoon, S. S., & Simon, M. C. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.10.012 · Cited by 93
Self-citationWiśniewski, J. R., Duś‐Szachniewicz, K., Ostasiewicz, P., Ziolkowski, P. P., Rakus, D., & Mann, M. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00523 · Cited by 94
Chen, X., Li, Z., Yong, H., Wang, W., Wang, D., Chu, S., Li, M., Hou, P., Zheng, J., & Bai, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.03.023 · Cited by 84
Sun, Z., Tao, W., Guo, X., Jing, C., Zhang, M., Wang, Z., Kong, F., Suo, N., Jiang, S., & Wang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.818984 · Cited by 84
Koide, S., Oshima, M., Takubo, K., Yamazaki, S., Nitta, E., Saraya, A., Aoyama, K., Kato, Y., Miyagi, S., Nakajima‐Takagi, Y., et al. (2016) · Blood · doi:10.1182/blood-2016-01-694810 · Cited by 87
Cell-Autonomous Metabolic Reprogramming in Hypoxia
Schito, L., & Rey, S. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.10.006 · Cited by 83
Teng, R., Liu, Z., Tang, H., Zhang, W., Chen, Y., Xu, R., Chen, L., Song, J., Liu, X., & Deng, H. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101218 · Cited by 81
Novel drugs that target the metabolic reprogramming in renal cell cancer
van der Mijn, J. C., Panka, D. J., Geissler, A. K., Verheul, H. M. W., & Mier, J. W. (2016) · Cancer & Metabolism · doi:10.1186/s40170-016-0154-8 · Cited by 83
SIRT3 Overexpression Inhibits Growth of Kidney Tumor Cells and Enhances Mitochondrial Biogenesis
Liu, H., Li, S., Liu, X., Chen, Y., & Deng, H. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00260 · Cited by 78
Snaebjornsson, M. T., & Schulze, A. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0065-6 · Cited by 79
Leishmania carbon metabolism in the macrophage phagolysosome- feast or famine?
McConville, M. J., Saunders, E. C., Kloehn, J., & Dagley, M. J. (2015) · F1000Research · doi:10.12688/f1000research.6724.1 · Cited by 76
Yuan, L., Zeng, G., Chen, L., Wang, G., Wang, X., Cao, X., Lü, M., Liu, X., Qian, G., Xiao, Y., et al. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.23574 · Cited by 76
Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures
Graham, N. A., Minasyan, A., Lomova, A., Cass, A. A., Balanis, N. G., Friedman, M., Chan, S. T., Zhao, S. R., Delgado, A., Go, J. L., et al. (2017) · Molecular Systems Biology · doi:10.15252/msb.20167159 · Cited by 78
Mahpour, A., & Mullen, A. C. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100177 · Cited by 75
Wang, Z., Li, M., Jiang, H., Luo, S., Shao, F., Xia, Y., Yang, M., Ren, X., Liu, T., Yan, M., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-01009-4 · Cited by 75
Glutathione-Dependent Pathways in Cancer Cells
Kalinina, E. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158423 · Cited by 79
Reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer
Luengo, A., Abbott, K. L., Davidson, S. M., Hosios, A. M., Faubert, B., Chan, S. H., Freinkman, E., Zacharias, L. G., Mathews, T. P., Clish, C. B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13419-4 · Cited by 75
Zhu, Y., Shi, M., Chen, H., Gu, J., Zhang, J., Shen, B., Deng, X., Xie, J., Zhan, X., & Peng, C. (2015) · Oncotarget · doi:10.18632/oncotarget.4167 · Cited by 73
Tang, H., Chen, Y., Liu, X., Wang, S., Lv, Y., Wu, D., Wang, Q., Luo, M., & Deng, H. (2016) · Oncotarget · doi:10.18632/oncotarget.9615 · Cited by 73
Feng, C., Li, Y., Li, K., Lyu, Y., Zhu, W., Jiang, H., & Wen, H. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02103-5 · Cited by 73
Rojas-Pirela, M., Andrade-Alviárez, D., Rojas, V., Kemmerling, U., Cáceres, A. J., Michels, P. A. M., Concepción, J. L., & Quiñones, W. A. (2020) · Open Biology · doi:10.1098/rsob.200302 · Cited by 71
mTORC2 controls cancer cell survival by modulating gluconeogenesis
Khan, M. W., Biswas, D., Ghosh, M., Mandloi, S., Chakrabarti, S., & Chakrabarti, P. (2015) · Cell Death Discovery · doi:10.1038/cddiscovery.2015.16 · Cited by 71
Low tumor glutathione level as a sensitivity marker for glutamate‑cysteine ligase inhibitors
Nishizawa, S., Araki, H., Ishikawa, Y., Kitazawa, S., Hata, A., Soga, T., & Hara, T. (2018) · Oncology Letters · doi:10.3892/ol.2018.8447 · Cited by 70
Okegawa, T., Morimoto, M., Nishizawa, S., Kitazawa, S., Honda, K., Araki, H., Tamura, T., Ando, A., Satomi, Y., Nutahara, K., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.04.009 · Cited by 71
Hoerner, C. R., Chen, V. J., & Fan, A. C. (2019) · Kidney Cancer · doi:10.3233/kca-180043 · Cited by 68
Polyamine Homeostasis in Development and Disease
Nakanishi, S., & Cleveland, J. L. (2021) · Medical Sciences · doi:10.3390/medsci9020028 · Cited by 68
Leithner, K., Triebl, A., Trötzmüller, M., Hinteregger, B., Leko, P., Wieser, B. I., Grasmann, G., Bertsch, A., Züllig, T., Stacher, E., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719871115 · Cited by 69
Li, Q., Wei, P., Wu, J., Zhang, M., Li, G., Li, Y., Xu, Y., Li, X., Xie, D., Cai, S., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0469-8 · Cited by 67
Hodakoski, C., Hopkins, B. D., Zhang, G., Su, T., Cheng, Z., Morris, R., Rhee, K. Y., Goncalves, M. D., & Cantley, L. C. (2019) · Cancers · doi:10.3390/cancers11010037 · Cited by 67
Wang, N., Zhang, C., Wang, W., Liu, J., Yu, Y., Li, Y., Zhang, M., Ge, X., Li, Q., & Miao, L. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1810-z · Cited by 66
Liu, P., Sun, S.-J., Ai, Y., Feng, X., Zheng, Y.-M., Gao, Y. L., Zhang, J., Zhang, L., Sun, Y., Xiong, Y., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04655-6 · Cited by 67
Zhang, J., Wang, J., Xing, H., Li, Q., Zhao, Q., & Li, J. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2595-8 · Cited by 66
Wang, Y., Qu, C., Liu, T., & Wang, C. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112612 · Cited by 69
TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling
Zhang, X., Li, S., He, J., Jin, Y., Zhang, R., Dong, W., Lin, M., Yang, Y., Tian, T., Zhou, Y., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3013 · Cited by 65
Metabolic reprogramming in keloid fibroblasts: Aerobic glycolysis and a novel therapeutic strategy
Li, Q., Qin, Z., Nie, F., Bi, H., Zhao, R., Pan, B., Ma, J., & Xie, X. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.01.068 · Cited by 65
A network of RNA-binding proteins controls translation efficiency to activate anaerobic metabolism
Ho, J. J. D., Balukoff, N. C., Theodoridis, P. R., Wang, M., Krieger, J. R., Schatz, J. H., & Lee, S. (2020) · Nature Communications · doi:10.1038/s41467-020-16504-1 · Cited by 66
Combinatorial Control of Plant Specialized Metabolism: Mechanisms, Functions, and Consequences
Lacchini, E., & Goossens, A. (2020) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-011620-031429 · Cited by 64
Yu, S., Hu, C., Cai, L., Du, X., Lin, F. Y., Yu, Q., Liu, L., Zhang, C. L., Liu, X., Li, W., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01778 · Cited by 64
RetractedMetabolic Pathways in Kidney Cancer: Current Therapies and Future Directions
Rathmell, W. K., Rathmell, J. C., & Linehan, W. M. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2309 · Cited by 68
Glycolysis‐Related Genes Serve as Potential Prognostic Biomarkers in Clear Cell Renal Cell Carcinoma
Zhang, Y., Chen, M., Liu, M., Xu, Y., & Wu, G. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6699808 · Cited by 63
Li, Z., You, Q., & Zhang, X. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01596 · Cited by 64
Moonlighting functions of glucose metabolic enzymes and metabolites in cancer
Guo, D. S., Meng, Y., Zhao, G., Wu, Q., & Lu, Z. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00800-3 · Cited by 67
Metabolomic study of human tissue and urine in clear cell renal carcinoma by LC-HRMS and PLS-DA
Nizioł, J., Bonifay, V., Ossoliński, K., Ossoliński, T., Ossolińska, A., Sunner, J. A., Beech, I. B., Arendowski, A., & Ruman, T. (2018) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-018-1059-x · Cited by 62
Glutathione Synthesis in Cancer Cells
Kalinina, E. V., & Гаврилюк, Л. А. (2020) · Biochemistry (Moscow) · doi:10.1134/s0006297920080052 · Cited by 62
Zalpoor, H., Aziziyan, F., Liaghat, M., Bakhtiyari, M., Akbari, A., Nabi‐Afjadi, M., Forghaniesfidvajani, R., & Rezaei, N. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00951-y · Cited by 63
Khan, M. A., Zubair, H., Anand, S., Srivastava, S. K., Singh, S., & Singh, A. P. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.003 · Cited by 61
Metabolic alterations in the tumor microenvironment and their role in oncogenesis
Eisenberg, L., Eisenberg‐Bord, M., Eisenberg‐Lerner, A., & Sagi‐Eisenberg, R. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.04.016 · Cited by 63
Sciacovelli, M., Dugourd, A. J. F., Valcárcel-Jiménez, L., Yang, M. H., Nikitopoulou, E., Costa, A. S. H., Tronci, L., Caraffini, V., Rodrigues, P., Schmidt, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35036-4 · Cited by 62
FBP1 controls liver cancer evolution from senescent MASH hepatocytes
Gu, L., Zhu, Y., Nandi, S. P., Lee, M., Watari, K., Bareng, B., Ohira, M., Liu, Y., Sakane, S., Carlessi, R., et al. (2025) · Nature · doi:10.1038/s41586-024-08317-9 · Cited by 63
Self-citationTurbitt, W. J., Rosean, C. B., Weber, K. S., & Norian, L. A. (2020) · Immunological Reviews · doi:10.1111/imr.12849 · Cited by 61
Hidden features: exploring the non-canonical functions of metabolic enzymes
Huangyang, P., & Simon, M. C. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.033365 · Cited by 60
Self-citationLiu, D., Xiao, Y., Zhou, B., Gao, S., Li, L., Zhao, L., Chen, W., Dai, B., Li, Q., Duan, H., et al. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa473 · Cited by 59
CBX3 promotes proliferation and regulates glycolysis via suppressing FBP1 in pancreatic cancer
Chen, L., Cheng, C., Qu, C., Wang, P., Chen, H., Meng, Z.-Q., & Chen, Z. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.04.137 · Cited by 58
Gluconeogenesis Flux in Metabolic Disease
Shah, A. M., & Wondisford, F. E. (2023) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061121-091507 · Cited by 59
The tumor microenvironment in renal cell cancer
Mier, J. W. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000512 · Cited by 58
Zhang, J., Li, S. Q., Lin, J. Q., Yu, W., & Eberlin, L. S. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-2522 · Cited by 57
Chen, S.-L., Huang, Q.-S., Huang, Y., Yang, X., Yang, M., He, Y., Cao, Y., Guan, X., & Yun, J. (2020) · Theranostics · doi:10.7150/thno.46825 · Cited by 56
Glycogen metabolism is dispensable for tumour progression in clear cell renal cell carcinoma
Xie, H. J., Song, J. H., Godfrey, J. T., Riscal, R., Skuli, N., Nissim, I., & Simon, M. C. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00367-x · Cited by 56
Self-citationGlutathione in cancer progression and chemoresistance: an update
Valenti, G. E., Tasso, B., Traverso, N., Domenicotti, C., & Marengo, B. (2023) · Redox Experimental Medicine · doi:10.1530/rem-22-0023 · Cited by 57
Han, X., Burrows, M., Kim, L. C., Xu, J. P., Vostrejs, W., Le, T. N. V., Poltorack, C. D., Jiang, Y., Cukierman, E., Stanger, B. Z., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114972 · Cited by 56
Self-citationFormation of Renal Cysts and Tumors in Vhl/Trp53 -Deficient Mice Requires HIF1α and HIF2α
Schönenberger, D., Harlander, S., Rajski, M., Jacobs, R. A., Lundby, A., Adlesic, M., Hejhal, T., Wild, P. J., Lundby, C., & Frew, I. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1859 · Cited by 58
Gatto, F., Volpi, N., Nilsson, H., Nookaew, I., Maruzzo, M., Roma, A., Johansson, M., Stierner, U. K., Lundstam, S., Basso, U., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.056 · Cited by 59
Kaushik, A., Tarangelo, A., Boroughs, L. K., Ragavan, M., Zhang, Y., Wu, C., Li, X., Ahumada, K., Chiang, J., Tcheuyap, V. T., et al. (2022) · Science Advances · doi:10.1126/sciadv.abp8293 · Cited by 56
Renal cell carcinoma: new insights and challenges for a clinician scientist
Shingarev, R. A., & Jaimes, E. A. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00480.2016 · Cited by 57
Li, H., Qi, Z., Niu, Y., Yang, Y., Li, M., Pang, Y., Liu, M., Cheng, X., Xu, M., & Wang, Z. (2021) · Oncogene · doi:10.1038/s41388-021-01957-5 · Cited by 55
Ji, Q., Li, H., Cai, Z., Yuan, X., Pu, X., Huang, Y., Fu, S., Chu, L., Jiang, C., Xue, J., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.76756 · Cited by 54
Metabolic alterations in hereditary and sporadic renal cell carcinoma
Coffey, N. J., & Simon, M. C. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00800-2 · Cited by 56
Self-citationInsulin and insulin-like growth factors act as renal cell cancer intratumoral regulators
Solarek, W., Koper, M., Lewicki, S., Szczylik, C. A., & Czarnecka, A. M. (2019) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-019-00512-y · Cited by 54
Regulation of Cancer Metabolism by Deubiquitinating Enzymes: The Warburg Effect
Kim, S., & Baek, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126173 · Cited by 59
Liu, G., Li, Q., Zhang, P.-F., Shen, S., Xie, W., Чэн, Б., Wu, J. H., Hu, W., Huang, X., & Peng, B. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1165-x · Cited by 53
Gamma-Glutamyltransferase 1 Promotes Clear Cell Renal Cell Carcinoma Initiation and Progression
Bansal, A., Sanchez, D. J., Nimgaonkar, V. U., Sánchez, D. L., Riscal, R., Skuli, N., & Simon, M. C. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1204 · Cited by 55
Self-citationRGS2-mediated translational control mediates cancer cell dormancy and tumor relapse
Cho, J., Min, H., Lee, H. J., Hyun, S. Y., Sim, J. Y., Noh, M., Hwang, S. J., Park, S., Boo, H., Lee, H., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci136779 · Cited by 53
Aerobic Glycolysis and the Warburg Effect. An Unexplored Realm in the Search for Fibrosis Therapies?
Maher, T. M. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201508-1699ed · Cited by 54
Zhao, W., Yang, S., Chen, J., Zhao, J., & Dong, J. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.09.009 · Cited by 52
Huang, M., Yang, L., Peng, X., Wei, S., Fan, Q., Yang, S., Li, X., Li, B., Jin, H., Wu, B., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01698-5 · Cited by 54
Self-citationWang, J., Zhang, P., Zhong, J., Tan, M., Ge, J., Tao, L., Li, Y., Zhu, Y., Wu, L., Qiu, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8382 · Cited by 55
Yang, J., Wang, C., Zhao, F., Luo, X., Qin, M., Arunachalam, E., Ge, Z., Wang, N., Deng, X., Jin, G., et al. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw109 · Cited by 52
Transcriptomic analysis of mitochondrial TFAM depletion changing cell morphology and proliferation
Lee, W. R., Na, H., Lee, S., Lim, W.-J., Kim, N., Lee, J. E., & Kang, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-18064-9 · Cited by 52
Decreased FBP1 expression rewires metabolic processes affecting aggressiveness of glioblastoma
Son, B., Lee, S., Kim, H., Kang, H., Jeon, J., Jo, S., Seong, K. M., Lee, S., Youn, H., & Youn, B. (2019) · Oncogene · doi:10.1038/s41388-019-0974-4 · Cited by 51
Fructose-1,6-bisphosphatase 1 dephosphorylates IκBα and suppresses colorectal tumorigenesis
Zhu, W., Chu, H., Zhang, Y., Luo, T., Yu, H. T., Zhu, H., Liu, Y., Gao, H., Zhao, Y., Li, Q., et al. (2023) · Cell Research · doi:10.1038/s41422-022-00773-0 · Cited by 50
Dai, J., Ji, Y., Wang, W., Kim, D., Yenwongfai, L. N., Wang, L., Luo, J., & Zhang, Z. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.06.014 · Cited by 51
KDM4A regulates HIF-1 levels through H3K9me3
Dobrynin, G., McAllister, T. E., Leszczyńska, K. B., Ramachandran, S., Krieg, A. J., Kawamura, A., & Hammond, E. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-11658-3 · Cited by 50
O’Mara, T. A., Zhao, M., & Spurdle, A. B. (2016) · Scientific Reports · doi:10.1038/srep36677 · Cited by 49
Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints
Xu, Y., He, L., Fu, Q., & Hu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.759015 · Cited by 51
Reprogramming of Metabolism in Kidney Cancer
Wettersten, H. I. (2020) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2019.12.002 · Cited by 49
Oxidative stress and metabolic reprogramming in Cr(VI) carcinogenesis
Clementino, M., Shi, X., & Zhang, Z. (2017) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2017.11.015 · Cited by 48
Winter, S., Fisel, P., Büttner, F., Rausch, S., D’Amico, D., Hennenlotter, J., Kruck, S., Nies, A. T., Stenzl, A., Junker, K., et al. (2016) · Scientific Reports · doi:10.1038/srep29930 · Cited by 48
Targeting FBPase is an emerging novel approach for cancer therapy
Liu, G., & Zhang, Y.-M. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0533-z · Cited by 47
Wang, Y., Dong, C., & Zhou, B. P. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.09.012 · Cited by 48
Addressing metabolic heterogeneity in clear cell renal cell carcinoma with quantitative Dixon MRI
Zhang, Y., Udayakumar, D., Cai, L., Hu, Z., Kapur, P., Kho, E.-Y., Pavía-Jiménez, A., Fulkerson, M., de Leon, A. D., Yuan, Q., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.94278 · Cited by 46
Fan, P., Wang, B., Meng, Z., Zhao, J., & Jin, X. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.08.014 · Cited by 45
Fructose 1,6- bis phosphatase: getting the message across
Timson, D. J. (2019) · Bioscience Reports · doi:10.1042/bsr20190124 · Cited by 45
PCK1 Regulates Glycolysis and Tumor Progression in Clear Cell Renal Cell Carcinoma Through LDHA
Shi, L., An, S., Liu, Y., Liu, J., & Wang, F. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s241717 · Cited by 45
Bacigalupa, Z. A., & Rathmell, W. K. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.034 · Cited by 47
Metabolic reprogramming in astrocytes results in neuronal dysfunction in intellectual disability
Zhang, H., Zheng, Q., Guo, T., Zhang, S., Zheng, S., Wang, R., Deng, Q., Yang, G., Zhang, S., Tang, L., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-022-01521-x · Cited by 38
Metadata
- Authors
- Li, B., Qiu, B., Lee, D. S. M., Walton, Z. E., Ochocki, J. D., Mathew, L. K., Mancuso, A., Gade, T. P. F., Keith, B., Nissim, I., & Simon, M. C.
- Affiliations
- Abramson Cancer Center (US)
- Howard Hughes Medical Institute (US)
- University of Pennsylvania (US)
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Simon, M. Celeste
- ORCID
- Venue
- Nature
- Published
- 2014-07-20
- Volume
- 513
- Issue
- 7517
- Pages
- 251-255
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4162811
- OpenAlex
- W2069663698
- Cited by
- 535
- References
- 31
- Citations by year
- 2026: 24 · 2025: 38 · 2024: 44 · 2023: 44 · 2022: 48 · 2021: 64 · 2020: 54 · 2019: 42 · 2018: 54 · 2017: 42 · 2016: 40 · 2015: 33 · 2014: 6
- FWCI
- 12.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health
- National Cancer Institute (F30CA177106, P01CA104838, CA104838, F32CA192758, P30CA016520)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK053761, DK-053761, R56DK053761)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- FBP1, clear cell renal cell carcinoma, von Hippel-Lindau protein, hypoxia-inducible factor, glycolysis, pentose phosphate pathway, Warburg effect, renal tubular epithelial cells, tumor progression, chromatin remodeling, cancer metabolism, epigenetic regulation, gluconeogenesis
- MeSH terms
- Animals, Carcinoma, Renal Cell, Cell Line, Epithelial Cells, Glycolysis, Fructose-Bisphosphatase, Humans, Kidney Neoplasms, Models, Molecular, NADP, Swine, Protein Structure, Tertiary, Disease Progression, Cell Line, Tumor, Cell Proliferation, Basic Helix-Loop-Helix Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
